Abstract
OBJECTIVEIt is unclear whether ACE gene polymorphisms influence the therapeutic outcome of a ACE‐inhibitor therapy. We therefore investigated the role of the ACE I/D polymorphism on 24‐hour blood pressure (ABPM), left ventricular mass index (LVMI) an proteinuria in children following ramipril monotherapy.METHODSSixty children (age 14.4±3.8 years) with various chronic nephropathies and hypertension received ramipril monotherapy (mean maximum dose 5.3±1.6 mg/m2). Their ACE I/D genotype was correlated to results of the 24‐h ABPM, LVMI and amount of proteinuria before and 6 months after treatment.RESULTSMean SDS blood pressure (BP) significantly dropped within 6 months (2.2±1.7 vs. 0.4±1.1 after 6 months, P<0.0001). This effect remains when patients are stratified according to the ACE II or DD genotype (mean SDS‐BP; II: 3.3±0.5 vs. 1.2±0.3, P=0.019; DD: 2.3±0.5 vs. 0.3±0.4, P=0.013). LVMI did not significantly differ before and following initiation of ramipril treatment and a stratification by ACE genotype did not reveal a difference either. However, proteinuria remained significantly higher in patients with the DD genotype.CONCLUSIONSRamipril is an efficacious antihypertensive therapy in children. Whereas the ACE genotype does not have an impact on the LVMI development, the DD‐allele seems to be negatively associated with the antiproteinuric effect of ramipril.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
